Squarepoint
GMAB icon

Squarepoint’s Genmab GMAB Stock Holding History

Squarepoint’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$927K Buy
+34,533
New +$1.03M ﹤0.01% 2830
2025
Q4 		– Sell
-9,480
Closed -$291K – 4492
2025
Q3 		$291K Sell
9,480
-84,753
-90% -$2.07M ﹤0.01% 3695
2025
Q2 		$1.95M Buy
94,233
+81,434
+636% +$1.67M ﹤0.01% 2124
2025
Q1 		$251K Sell
12,799
-104,708
-89% -$2.2M ﹤0.01% 3861
2024
Q4 		$2.45M Buy
117,507
+108,705
+1,235% +$2.39M ﹤0.01% 2238
2024
Q3 		$215K Buy
+8,802
New +$235K ﹤0.01% 3643
2024
Q2 		– Sell
-19,116
Closed -$572K – 4275
2024
Q1 		$572K Buy
19,116
+1,353
+8% +$39.7K ﹤0.01% 2955
2023
Q4 		$566K Buy
17,763
+5,550
+45% +$174K ﹤0.01% 2912
2023
Q3 		$431K Sell
12,213
-7,766
-39% -$296K ﹤0.01% 2905
2023
Q2 		$759K Buy
19,979
+1,235
+7% +$49.2K ﹤0.01% 2366
2023
Q1 		$708K Sell
18,744
-1,467
-7% -$56.4K ﹤0.01% 2106
2022
Q4 		$857K Sell
20,211
-26,979
-57% -$1.11M ﹤0.01% 1925
2022
Q3 		$1.52M Buy
+47,190
New +$1.66M 0.01% 1498
2021
Q1 		– Sell
-9,231
Closed -$375K – 3294
2020
Q4 		$375K Buy
+9,231
New +$345K ﹤0.01% 2040

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Squarepoint's GMAB Position: Q1 2026 in Review

Squarepoint opened a new position in Genmab (GMAB) in Q1 2026: 34,533 shares worth $927K. The stake represents ﹤0.01% of the portfolio and ranks #2830 among its holdings. This is a return to the name: Squarepoint previously reported a position in GMAB as recently as Q3 2025.

Squarepoint first reported a position in GMAB in Q4 2020 and has held it in 14 quarters since. The position peaked at $2.45M in Q4 2024. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Squarepoint held 34,533 shares of Genmab worth $927K as of Q1 2026.
  • Genmab was a new Squarepoint position in Q1 2026.
  • Genmab made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2830 holding.
  • Squarepoint first reported a position in Genmab in Q4 2020 and has held it in 14 quarters since.
  • Squarepoint's Genmab position peaked at $2.45M in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.